Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Ebola virus vaccination and the longevity of total versus neutralising antibody response-is it enough?

Bornholdt ZA, Bradfute SB.

Lancet Infect Dis. 2018 Jul;18(7):699-700. doi: 10.1016/S1473-3099(18)30175-0. Epub 2018 Apr 5. No abstract available.

PMID:
29627146
2.

Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines.

Clarke EC, Collar AL, Ye C, CaƬ Y, Anaya E, Rinaldi D, Martinez B, Yarborough S, Merle C, Theisen M, Wada J, Kuhn JH, Bradfute SB.

Sci Rep. 2017 Nov 8;7(1):15091. doi: 10.1038/s41598-017-15416-3.

3.

Advances in Ebola virus vaccination.

Clarke EC, Bradfute SB.

Lancet Infect Dis. 2017 Aug;17(8):787-788. doi: 10.1016/S1473-3099(17)30320-1. Epub 2017 Jun 9. No abstract available.

PMID:
28606592
4.

Comparison of N- and O-linked glycosylation patterns of ebolavirus glycoproteins.

Collar AL, Clarke EC, Anaya E, Merrill D, Yarborough S, Anthony SM, Kuhn JH, Merle C, Theisen M, Bradfute SB.

Virology. 2017 Feb;502:39-47. doi: 10.1016/j.virol.2016.12.010. Epub 2016 Dec 13.

5.

The early clinical development of Ebola virus treatments.

Bradfute SB.

Expert Opin Investig Drugs. 2017 Jan;26(1):1-4. doi: 10.1080/13543784.2017.1260545. Epub 2016 Nov 21. No abstract available.

PMID:
27838928
6.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G.

PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.

7.

Duration of immune responses after Ebola virus vaccination.

Bradfute SB.

Lancet Infect Dis. 2016 Jan;16(1):2-3. doi: 10.1016/S1473-3099(15)00408-9. Epub 2015 Nov 4. No abstract available.

8.

Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.

Chauhan S, Ahmed Z, Bradfute SB, Arko-Mensah J, Mandell MA, Won Choi S, Kimura T, Blanchet F, Waller A, Mudd MH, Jiang S, Sklar L, Timmins GS, Maphis N, Bhaskar K, Piguet V, Deretic V.

Nat Commun. 2015 Oct 27;6:8620. doi: 10.1038/ncomms9620.

9.

Filoviruses: One of These Things is (not) Like the Other.

Anthony SM, Bradfute SB.

Viruses. 2015 Sep 29;7(10):5172-90. doi: 10.3390/v7102867. Review.

10.

Eastern equine encephalitis virus in mice I: clinical course and outcome are dependent on route of exposure.

Honnold SP, Mossel EC, Bakken RR, Fisher D, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Erwin-Cohen R, Bradfute SB, Maheshwari RK, Glass PJ.

Virol J. 2015 Sep 29;12:152. doi: 10.1186/s12985-015-0386-1.

11.

Mechanisms of immunity in post-exposure vaccination against Ebola virus infection.

Bradfute SB, Anthony SM, Stuthman KS, Ayithan N, Tailor P, Shaia CI, Bray M, Ozato K, Bavari S.

PLoS One. 2015 Mar 18;10(3):e0118434. doi: 10.1371/journal.pone.0118434. eCollection 2015.

12.

Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development.

Brett M, Bradfute SB.

Curr Pharm Des. 2015;21(16):2131-5. Review.

PMID:
25760341
13.

Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Bavari S, Bray M, Ozato K.

PLoS One. 2015 Feb 26;10(2):e0118345. doi: 10.1371/journal.pone.0118345. eCollection 2015.

14.

Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.

Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K.

J Interferon Cytokine Res. 2014 Feb;34(2):79-89. doi: 10.1089/jir.2013.0035. Epub 2013 Oct 8.

15.

Autophagy as an immune effector against tuberculosis.

Bradfute SB, Castillo EF, Arko-Mensah J, Chauhan S, Jiang S, Mandell M, Deretic V.

Curr Opin Microbiol. 2013 Jun;16(3):355-65. doi: 10.1016/j.mib.2013.05.003. Epub 2013 Jun 18. Review.

16.

Mouse models for filovirus infections.

Bradfute SB, Warfield KL, Bray M.

Viruses. 2012 Sep;4(9):1477-508. doi: 10.3390/v4091477. Epub 2012 Sep 7. Review.

17.

TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation.

Pilli M, Arko-Mensah J, Ponpuak M, Roberts E, Master S, Mandell MA, Dupont N, Ornatowski W, Jiang S, Bradfute SB, Bruun JA, Hansen TE, Johansen T, Deretic V.

Immunity. 2012 Aug 24;37(2):223-34. doi: 10.1016/j.immuni.2012.04.015.

18.

Correlates of immunity to filovirus infection.

Bradfute SB, Bavari S.

Viruses. 2011 Jul;3(7):982-1000. doi: 10.3390/v3070982. Epub 2011 Jun 27. Review.

19.

Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.

Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, Bradfute SB, Gearhart JD, Retterer C, Kranzusch PJ, Misasi JN, Hogenbirk MA, Wahl-Jensen V, Volchkov VE, Cunningham JM, Jahrling PB, Aman MJ, Bavari S, Farzan M, Kuhn JH.

J Virol. 2011 Sep;85(17):8502-13. doi: 10.1128/JVI.02600-10. Epub 2011 Jun 22.

20.

A STAT-1 knockout mouse model for Machupo virus pathogenesis.

Bradfute SB, Stuthman KS, Shurtleff AC, Bavari S.

Virol J. 2011 Jun 14;8:300. doi: 10.1186/1743-422X-8-300.

21.

Filovirus vaccines.

Bradfute SB, Dye JM Jr, Bavari S.

Hum Vaccin. 2011 Jun;7(6):701-11. Epub 2011 Jun 1. Review.

22.

Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies.

Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S.

Antiviral Res. 2011 May;90(2):85-92. doi: 10.1016/j.antiviral.2011.02.010. Epub 2011 Mar 6. Review.

PMID:
21362441
23.

Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.

Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, Wood SC, Bavari S, Kaplan GG.

Vaccine. 2011 Apr 5;29(16):2968-77. doi: 10.1016/j.vaccine.2011.01.113. Epub 2011 Feb 15.

24.

Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis.

Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, Bavari S.

J Immunol. 2010 Jan 1;184(1):327-35. doi: 10.4049/jimmunol.0901231.

25.

Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.

Panchal RG, Bradfute SB, Peyser BD, Warfield KL, Ruthel G, Lane D, Kenny TA, Anderson AO, Raschke WC, Bavari S.

Cell Host Microbe. 2009 Aug 20;6(2):162-73. doi: 10.1016/j.chom.2009.07.003.

26.

Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.

Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, Ozato K.

PLoS Pathog. 2009 Jun;5(6):e1000493. doi: 10.1371/journal.ppat.1000493. Epub 2009 Jun 26.

27.

Development and characterization of a mouse model for Marburg hemorrhagic fever.

Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S.

J Virol. 2009 Jul;83(13):6404-15. doi: 10.1128/JVI.00126-09. Epub 2009 Apr 15.

28.

Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis.

Panchal RG, Ulrich RL, Bradfute SB, Lane D, Ruthel G, Kenny TA, Iversen PL, Anderson AO, Gussio R, Raschke WC, Bavari S.

J Biol Chem. 2009 May 8;284(19):12874-85. doi: 10.1074/jbc.M809633200. Epub 2009 Mar 6.

29.

Hematopoietic fingerprints: an expression database of stem cells and their progeny.

Chambers SM, Boles NC, Lin KY, Tierney MP, Bowman TV, Bradfute SB, Chen AJ, Merchant AA, Sirin O, Weksberg DC, Merchant MG, Fisk CJ, Shaw CA, Goodell MA.

Cell Stem Cell. 2007 Nov;1(5):578-91. doi: 10.1016/j.stem.2007.10.003.

30.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

31.

Lymphocyte death in a mouse model of Ebola virus infection.

Bradfute SB, Braun DR, Shamblin JD, Geisbert JB, Paragas J, Garrison A, Hensley LE, Geisbert TW.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S296-304.

PMID:
17940964
32.

Development of a model for marburgvirus based on severe-combined immunodeficiency mice.

Warfield KL, Alves DA, Bradfute SB, Reed DK, VanTongeren S, Kalina WV, Olinger GG, Bavari S.

Virol J. 2007 Oct 25;4:108.

33.

Differential mRNA processing in hematopoietic stem cells.

Bowman TV, McCooey AJ, Merchant AA, Ramos CA, Fonseca P, Poindexter A, Bradfute SB, Oliveira DM, Green R, Zheng Y, Jackson KA, Chambers SM, McKinney-Freeman SL, Norwood KG, Darlington G, Gunaratne PH, Steffen D, Goodell MA.

Stem Cells. 2006 Mar;24(3):662-70. Epub 2005 Dec 22.

34.

Roles of Sca-1 in hematopoietic stem/progenitor cell function.

Bradfute SB, Graubert TA, Goodell MA.

Exp Hematol. 2005 Jul;33(7):836-43.

PMID:
15963860
35.

Cardiac muscle plasticity in adult and embryo by heart-derived progenitor cells.

Oh H, Chi X, Bradfute SB, Mishina Y, Pocius J, Michael LH, Behringer RR, Schwartz RJ, Entman ML, Schneider MD.

Ann N Y Acad Sci. 2004 May;1015:182-9. Review.

PMID:
15201159
36.

Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction.

Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12313-8. Epub 2003 Oct 6.

37.

Adenoviral transduction of mouse hematopoietic stem cells.

Bradfute SB, Goodell MA.

Mol Ther. 2003 Mar;7(3):334-40.

Supplemental Content

Loading ...
Support Center